

IN THE CLAIMS

Claims 1-73. (Canceled)

Claim 74. (Currently amended) An isolated nucleic acid molecule which encodes a ~~protein~~ polypeptide consisting of an immunoreactive portion of the protein encoded by an isolated nucleic acid molecule, the complementary sequence of which hybridizes to the nucleotide sequence of SEQ ID NO: 1, at 65°C, for 18 hours, followed by four one hour washes at 2xSSC, 0.1% SDS, and a final wash at 0.2xSSC.

Claim 75. (Currently amended) ~~The~~ An isolated nucleic acid molecule which encodes a ~~protein~~ polypeptide consisting of an immunoreactive portion of the protein encoded by an isolated nucleic acid molecule, the complementary sequence of which hybridizes to the nucleotide sequence of SEQ ID NO: 1, at 65°C, for 18 hours, followed by four one hour washes at 2xSSC, 0.1% SDS, and a final wash at 0.2xSSC. ~~of claim 74, wherein said immunoreactive portion is an amino acid sequence of a tumor rejection antigen.~~

Claim 76. (Previously presented) The isolated nucleic acid molecule of claim 75, wherein said tumor rejection antigen binds to an MHC-Class I molecule.

Claim 77. (Previously presented) The isolated nucleic acid molecule of claim 75, wherein said tumor rejection antigen binds to an MHC-Class II molecule.

Claim 78. (Previously presented) The isolated nucleic acid molecule of claim 77 which consists of a nucleotide sequence which encodes an isolated polypeptide consisting of an amino acid sequence found in the protein encoded by SEQ ID NO: 1, wherein said polypeptide comprises at least 18 and no more than 25 amino acids.

- Claim 79. (Previously presented) The isolated nucleic acid molecule of claim 78, wherein said isolated polypeptide is SEQ ID NOS.: 8, 9, 10, 11, 12, or 13.
- Claim 80. (Previously presented) The isolated nucleic acid molecule of claim 76, wherein said amino acid sequence is set forth in SEQ ID NO: 4, 5, or 6.
- Claim 81. (Currently Amended) ~~Expression~~ An expression vector comprising the isolated nucleic acid molecule of claim 74, operably linked to a promoter.
- Claim 82. (Currently Amended) ~~Expression~~ An expression vector comprising the isolated nucleic acid molecule of claim 78, operably limited to a promoter.
- Claim 83. (Previously presented) The expression vector of claim 81, which is adenovirus based.
- Claim 84. (Currently Amended) ~~Eukaryotic~~ An eukaryotic cell transformed or transfected with the expression vector of claim 81.
- Claim 85. (Currently Amended) ~~Expression~~ An expression kit comprising a separate portion of each of
- (i) an isolated nucleic acid molecule claim 78, and
 - (ii) an isolated nucleic acid molecule which encodes an MHC-Class II molecule.
- Claim 86. (Currently amended) ~~Recombinant~~ A recombinant cell comprising the isolated nucleic acid molecule of claim 78.
- Claim 87. (Currently amended) ~~Recombinant~~ A recombinant cell comprising the expression vector of claim 82.

- Claim 88. (Currently amended) ~~Method~~ A method for preventing onset of a cancerous condition in a subject comprising administering an amount of the expression vector of claim 82 in an amount sufficient to prevent onset of said cancerous conditions in said subject.
- Claim 89. (Previously presented) An isolated nucleic acid molecule which consists of a nucleotide sequence which encodes the peptide set forth in SEQ ID NO: 7.
- Claim 90. (Currently amended) ~~Expression~~ An expression vector comprising the isolated nucleic acid molecule of claim 89, operably linked to a promoter.
- Claim 91. (Currently amended) ~~Recombinant~~ A recombinant cell comprising the isolated nucleic acid molecule of claim 89.
- Claim 92. (Currently amended) ~~Recombinant~~ A recombinant cell comprising the expression vector of claim 90.
- Claim 93. (Currently amended) ~~Non-proliferative~~ A non-proliferative cell which expresses the complex of claim 90.
- Claim 94. (Currently amended) ~~Composition~~ A composition comprising the non-proliferative cell of claim 93, and an adjuvant.